FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310593690> ?p ?o ?g. }

• W4310593690 endingPage "e1083" @default.
• W4310593690 startingPage "e1072" @default.
• W4310593690 abstract "Background and Objectives GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) are rare, autosomal recessive, neurodegenerative diseases with no available symptomatic or disease-modifying treatments. This clinical trial investigated N-acetyl- l -leucine (NALL), an orally administered, modified amino acid in pediatric (≥6 years) and adult patients with GM2 gangliosidoses. Methods In this phase IIb, multinational, open-label, rater-blinded study (IB1001-202), male and female patients aged ≥6 years with a genetically confirmed diagnosis of GM2 gangliosidoses received orally administered NALL for a 6-week treatment period (4 g/d in patients ≥13 years, weight-tiered doses for patients 6–12 years), followed by a 6-week posttreatment washout period. For the primary Clinical Impression of Change in Severity analysis, patient performance on a predetermined primary anchor test (the 8-Meter Walk Test or the 9-Hole Peg Test) at baseline, after 6 weeks on NALL, and again after a 6-week washout period was videoed and evaluated centrally by blinded raters. Secondary outcomes included assessments of ataxia, clinical global impression, and quality of life. Results Thirty patients between the age of 6 and 55 years were enrolled. Twenty-nine had an on-treatment assessment and were included in the primary modified intention-to-treat analysis. The study met its CI-CS primary end point (mean difference 0.71, SD = 2.09, 90% CI 0.00, 1.50, p = 0.039), as well as secondary measures of ataxia and global impression. NALL was safe and well tolerated, with no serious adverse reactions. Discussion Treatment with NALL was associated with statistically significant and clinically relevant changes in functioning and quality of life in patients with GM2 gangliosidosis. NALL was safe and well tolerated, contributing to an overall favorable risk:benefit profile. NALL is a promising, easily administered (oral) therapeutic option for these rare, debilitating diseases with immense unmet medical needs. Trial Registration Information The trial is registered with ClinicalTrials.gov (NCT03759665; registered on November 30, 2018), EudraCT (2018-004406-25), and DRKS (DRKS00017539). The first patient was enrolled on June 7, 2019. Classification of Evidence This study provides Class IV evidence that NALL improves outcomes for patients with GM2 gangliosidoses." @default.
• W4310593690 created "2022-12-12" @default.
• W4310593690 creator A5015465869 @default.
• W4310593690 creator A5022227939 @default.
• W4310593690 creator A5026428280 @default.
• W4310593690 creator A5027633483 @default.
• W4310593690 creator A5029675348 @default.
• W4310593690 creator A5031435836 @default.
• W4310593690 creator A5040729727 @default.
• W4310593690 creator A5058641127 @default.
• W4310593690 creator A5066632194 @default.
• W4310593690 creator A5067530404 @default.
• W4310593690 creator A5076949222 @default.
• W4310593690 creator A5081155368 @default.
• W4310593690 creator A5082051712 @default.
• W4310593690 creator A5091346458 @default.
• W4310593690 date "2023-03-07" @default.
• W4310593690 modified "2023-10-09" @default.
• W4310593690 title "Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses" @default.
• W4310593690 cites W2083930723 @default.
• W4310593690 cites W2108116414 @default.
• W4310593690 cites W2117257456 @default.
• W4310593690 cites W2129415962 @default.
• W4310593690 cites W2397368147 @default.
• W4310593690 cites W2462837143 @default.
• W4310593690 cites W2795823005 @default.
• W4310593690 cites W2886544055 @default.
• W4310593690 cites W2917235576 @default.
• W4310593690 cites W3007100847 @default.
• W4310593690 cites W3015871979 @default.
• W4310593690 cites W3047322234 @default.
• W4310593690 cites W3083346065 @default.
• W4310593690 cites W3092516038 @default.
• W4310593690 cites W3121664580 @default.
• W4310593690 cites W3157386383 @default.
• W4310593690 cites W3188004113 @default.
• W4310593690 cites W3189943578 @default.
• W4310593690 doi "https://doi.org/10.1212/wnl.0000000000201660" @default.
• W4310593690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36456200" @default.
• W4310593690 hasPublicationYear "2023" @default.
• W4310593690 type Work @default.
• W4310593690 citedByCount "3" @default.
• W4310593690 countsByYear W43105936902023 @default.
• W4310593690 crossrefType "journal-article" @default.
• W4310593690 hasAuthorship W4310593690A5015465869 @default.
• W4310593690 hasAuthorship W4310593690A5022227939 @default.
• W4310593690 hasAuthorship W4310593690A5026428280 @default.
• W4310593690 hasAuthorship W4310593690A5027633483 @default.
• W4310593690 hasAuthorship W4310593690A5029675348 @default.
• W4310593690 hasAuthorship W4310593690A5031435836 @default.
• W4310593690 hasAuthorship W4310593690A5040729727 @default.
• W4310593690 hasAuthorship W4310593690A5058641127 @default.
• W4310593690 hasAuthorship W4310593690A5066632194 @default.
• W4310593690 hasAuthorship W4310593690A5067530404 @default.
• W4310593690 hasAuthorship W4310593690A5076949222 @default.
• W4310593690 hasAuthorship W4310593690A5081155368 @default.
• W4310593690 hasAuthorship W4310593690A5082051712 @default.
• W4310593690 hasAuthorship W4310593690A5091346458 @default.
• W4310593690 hasBestOaLocation W43105936902 @default.
• W4310593690 hasConcept C118552586 @default.
• W4310593690 hasConcept C126322002 @default.
• W4310593690 hasConcept C141071460 @default.
• W4310593690 hasConcept C187212893 @default.
• W4310593690 hasConcept C197934379 @default.
• W4310593690 hasConcept C203092338 @default.
• W4310593690 hasConcept C2779134260 @default.
• W4310593690 hasConcept C2779390119 @default.
• W4310593690 hasConcept C2780906641 @default.
• W4310593690 hasConcept C535046627 @default.
• W4310593690 hasConcept C71924100 @default.
• W4310593690 hasConceptScore W4310593690C118552586 @default.
• W4310593690 hasConceptScore W4310593690C126322002 @default.
• W4310593690 hasConceptScore W4310593690C141071460 @default.
• W4310593690 hasConceptScore W4310593690C187212893 @default.
• W4310593690 hasConceptScore W4310593690C197934379 @default.
• W4310593690 hasConceptScore W4310593690C203092338 @default.
• W4310593690 hasConceptScore W4310593690C2779134260 @default.
• W4310593690 hasConceptScore W4310593690C2779390119 @default.
• W4310593690 hasConceptScore W4310593690C2780906641 @default.
• W4310593690 hasConceptScore W4310593690C535046627 @default.
• W4310593690 hasConceptScore W4310593690C71924100 @default.
• W4310593690 hasIssue "10" @default.
• W4310593690 hasLocation W43105936901 @default.
• W4310593690 hasLocation W43105936902 @default.
• W4310593690 hasLocation W43105936903 @default.
• W4310593690 hasOpenAccess W4310593690 @default.
• W4310593690 hasPrimaryLocation W43105936901 @default.
• W4310593690 hasRelatedWork W113810927 @default.
• W4310593690 hasRelatedWork W1586374228 @default.
• W4310593690 hasRelatedWork W2003938723 @default.
• W4310593690 hasRelatedWork W2047967234 @default.
• W4310593690 hasRelatedWork W2118496982 @default.
• W4310593690 hasRelatedWork W2364998975 @default.
• W4310593690 hasRelatedWork W2369162477 @default.
• W4310593690 hasRelatedWork W2439875401 @default.
• W4310593690 hasRelatedWork W4238867864 @default.
• W4310593690 hasRelatedWork W2525756941 @default.
• W4310593690 hasVolume "100" @default.

• next